Soligenix Inc
SNGX1.380USD
+0.150+12.20%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
13.61MMarket Cap
LossP/E TTM
More Details of Soligenix Inc Company
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Soligenix Inc Info
Ticker SymbolSNGX
Company nameSoligenix Inc
IPO dateApr 04, 1994
CEOSchaber (Christopher J)
Number of employees14
Security typeOrdinary Share
Fiscal year-endApr 04
Address29 Emmons Drive
CityPRINCETON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08540
Phone16095388200
Websitehttps://www.soligenix.com/
Ticker SymbolSNGX
IPO dateApr 04, 1994
CEOSchaber (Christopher J)
Company Executives of Soligenix Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
15.51K
+3992.61%
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
96.00
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Jonathan L. Guarino, CPA
Mr. Jonathan L. Guarino, CPA
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
--
--
Dr. Oreola Donini, Ph.D.
Dr. Oreola Donini, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
15.51K
+3992.61%
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
96.00
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 5
Updated: Fri, Dec 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
7.02%
Intracoastal Capital, L.L.C.
4.21%
DRW Securities, LLC
1.70%
Two Sigma Investments, LP
0.87%
Sabby Management, LLC
0.80%
Other
85.40%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
7.02%
Intracoastal Capital, L.L.C.
4.21%
DRW Securities, LLC
1.70%
Two Sigma Investments, LP
0.87%
Sabby Management, LLC
0.80%
Other
85.40%
Shareholder Types
Shareholders
Proportion
Hedge Fund
8.66%
Corporation
4.21%
Investment Advisor
3.26%
Investment Advisor/Hedge Fund
1.35%
Research Firm
0.51%
Individual Investor
0.16%
Other
81.85%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
42
242.17K
2.89%
-108.56K
2025Q2
50
150.04K
4.60%
-125.61K
2025Q1
50
149.55K
4.59%
-122.83K
2024Q4
62
34.48K
1.37%
-224.66K
2024Q3
62
66.84K
2.91%
-140.04K
2024Q2
61
101.18K
6.59%
-9.86K
2024Q1
57
15.87K
2.48%
-90.98K
2023Q4
55
24.60K
3.87%
-67.56K
2023Q3
57
57.20K
9.40%
-37.02K
2023Q2
61
91.32K
18.32%
+80.79K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Intracoastal Capital, L.L.C.
425.00K
5.08%
+425.00K
--
Sep 25, 2025
The Vanguard Group, Inc.
2.19K
0.03%
--
--
Aug 31, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
Date
Type
Ratio
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
FAQs
Who are the top five shareholders of Soligenix Inc?
The top five shareholders of Soligenix Inc are:
Intracoastal Capital, L.L.C. holds 425.00K shares, accounting for 5.08% of the total shares.
The Vanguard Group, Inc. holds 2.19K shares, accounting for 0.03% of the total shares.
Intracoastal Capital, L.L.C. holds 425.00K shares, accounting for 5.08% of the total shares.
The Vanguard Group, Inc. holds 2.19K shares, accounting for 0.03% of the total shares.
What are the top three shareholder types of Soligenix Inc?
The top three shareholder types of Soligenix Inc are:
Armistice Capital LLC
Intracoastal Capital, L.L.C.
DRW Securities, LLC
Armistice Capital LLC
Intracoastal Capital, L.L.C.
DRW Securities, LLC
How many institutions hold shares of Soligenix Inc (SNGX)?
As of 2025Q3, 42 institutions hold shares of Soligenix Inc, with a combined market value of approximately 242.17K, accounting for 2.89% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.70%.
What is the biggest source of revenue for Soligenix Inc?
In --, the -- business generated the highest revenue for Soligenix Inc, amounting to -- and accounting for --% of total revenue.
